Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2024 / Articles / Dec / Charting the Rise of Cell and Gene Therapies
Manufacture Advanced Medicine

Charting the Rise of Cell and Gene Therapies

We look back on a decade of breakthroughs in advanced medicine – explore our top articles on cell and gene therapy.

12/31/2024 1 min read

Share

The Medicine Maker has spent 10 years publishing interviews, articles and commentary covering the entire spectrum of drug development and manufacturing. Here, we look back on the field of advanced medicine. Cell and gene therapies have seen incredible progress over the past decade, including the approval of the world’s first approved CAR T therapy. We celebrate the achievements of the field by taking a look at some of our top articles.

A Guiding Light for CRISPR

The story of how Caribou Biosciences developed a hybrid RNA-DNA guide to increase Cas9 specificity – and what the name of the technology has got to do with the Burgundy wine region in France…

Read the article

Memories From the Start of the Gene Therapy Wave: Lessons Learned with Alan Boyd

The remarkable story of gene therapy drug development during the 1990s and early 2000s

Read the article

TILs Taking on Solid Tumors

Looking into the development of Amtagvi – the world’s first approved T-cell therapy for a solid tumor

Read the article

Cell and Gene 4.0

May the fourth industrial revolution be with you…

Read the article

Advanced – But Not Advanced Enough

Great successes are being seen in gene therapy, but there are still gaps in our scientific knowledge – and our manufacturing prowess

Read the article

Less Than 5 Percent Human Effort: Thoughts on the Role of Automation on Cell and Gene Therapy

We all know that automation can reduce human labor, but how else can it make economically viable cell and gene therapies a reality?

Read the article

Titan on the Horizon

Mammoth-resurrection company Colossal has spawned a digital pharma entity that wants to take cell and gene therapy to its next stage of evolution

Read the article

Weathering the Storm: Cell and Gene’s Economic Downturn

An early wave of investor enthusiasm followed by an economic crisis has landed our field in a sea of trouble – so how can we swim to shore?

Read the article

Dreaming of an Efficient Future

The rapid rise of cell and gene therapies took the industry by surprise. We know these therapies can be commercialized; but to do so efficiently, we must turn our attention to new challenges, including optimized manufacturing strategies and streamlined patient access.

Read the article

Of Plumbing and Poetry

Sitting Down With… Sandy Macrae, Chief Executive Officer, Sangamo Therapeutics, USA

Read the article

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

Don’t Forget CDx Developers
Advanced Medicine
Don’t Forget CDx Developers

November 7, 2014

0 min read

Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Trump Effect on Cell and Gene: Science versus Shockwaves
Business Practice Standards & Regulation Trends & Forecasts Advanced Medicine
The Trump Effect on Cell and Gene: Science versus Shockwaves

April 1, 2025

9 min read

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.